tradingkey.logo
tradingkey.logo
Search

Eli Lilly and Co

LLY
Add to Watchlist
1208.120USD
+79.000+7.01%
Close 06/26, 16:00ETQuotes delayed by 15 min
1.14TMarket Cap
42.84P/E TTM

More Details of Eli Lilly and Co Company

Eli Lilly and Company, commonly referred to as Lilly, is an American multinational pharmaceutical corporation based in Indianapolis, Indiana, with offices in 18 countries and products available in approximately 125 nations. Founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran from the American Civil War, the company carries his name.

As of October 2024, Lilly has achieved the status of the most valuable drug company in the world, boasting a market capitalization of $842 billion, marking the highest valuation ever recorded for a pharmaceutical company. The firm ranks 127th on the Fortune 500, reporting revenues of $34.12 billion. Additionally, it is positioned 221st on the Forbes Global 2000 list, which encompasses the largest publicly traded companies globally, and 252nd on Forbes' list of "America's Best Employers."

Lilly is recognized for its antidepressant medications, including Prozac and Cymbalta, as well as the antipsychotic drug Zyprexa. Its primary revenue sources are the diabetes treatments Humalog and Trulicity.

The company was a pioneer in mass-producing both the polio vaccine, created in 1955 by Jonas Salk, and insulin. Lilly was among the first in the pharmaceutical sector to manufacture human insulin using recombinant DNA technology, producing products like Humulin, Humalog, and the first approved biosimilar insulin in the U.S., known as Basaglar. Additionally, Lilly introduced exenatide to the market as the first of the GLP-1 receptor agonists, followed by highly successful medications in this category, such as Mounjaro and Zepbound.

By 1997, Lilly had become both the largest corporation and the largest philanthropic benefactor in Indiana. In 2009, it pleaded guilty to illegally marketing Zyprexa and agreed to a substantial $1.415 billion settlement, which included a criminal fine of $515 million, making it the largest ever in a healthcare-related case and the highest criminal fine levied against a single corporation in a U.S. criminal prosecution at that time.

Lilly is a full member of the Pharmaceutical Research and Manufacturers of America, as well as the European Federation of Pharmaceutical Industries and Associations.

Eli Lilly and Co Info

Ticker SymbolLLY
Company nameEli Lilly and Co
IPO dateJul 09, 1970
CEORicks (David A)
Number of employees47000
Security typeOrdinary Share
Fiscal year-endJul 09
AddressLilly Corporate Ctr
CityINDIANAPOLIS
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code46285
Phone13172762000
Websitehttps://www.lilly.com/
Ticker SymbolLLY
IPO dateJul 09, 1970
CEORicks (David A)

Company Executives of Eli Lilly and Co

Name
Name/Position
Position
Shareholding
Change
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+11.64%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
61.12K
+11.45%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
55.56K
+53.81%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
46.10K
+13.81%
Mr. Ilya Yuffa
Mr. Ilya Yuffa
Executive Vice President, President of Lilly International
Executive Vice President, President of Lilly International
29.80K
-8.39%
Mr. Diogo Rau
Mr. Diogo Rau
Executive Vice President, Chief Information and Digital Officer
Executive Vice President, Chief Information and Digital Officer
26.40K
+25.30%
Dr. Katherine Baicker, Ph.D.
Dr. Katherine Baicker, Ph.D.
Independent Director
Independent Director
23.54K
+0.70%
Mr. Lucas E. Montarce
Mr. Lucas E. Montarce
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
16.26K
+9.66%
Mr. Eric Dozier
Mr. Eric Dozier
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
14.46K
+31.93%
Ms. Kimberly H. Johnson
Ms. Kimberly H. Johnson
Independent Director
Independent Director
3.27K
+0.67%
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+11.64%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
61.12K
+11.45%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
55.56K
+53.81%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
46.10K
+13.81%
Mr. Ilya Yuffa
Mr. Ilya Yuffa
Executive Vice President, President of Lilly International
Executive Vice President, President of Lilly International
29.80K
-8.39%
Mr. Diogo Rau
Mr. Diogo Rau
Executive Vice President, Chief Information and Digital Officer
Executive Vice President, Chief Information and Digital Officer
26.40K
+25.30%

FAQs

Who are the top five shareholders of Eli Lilly and Co?

The top five shareholders of Eli Lilly and Co are: Ms. Anne E. White

How many institutions hold shares of Eli Lilly and Co (LLY)?

As of 2026Q1, 6331 institutions hold shares of Eli Lilly and Co, with a combined market value of approximately 864.16M, accounting for 91.72% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 69007266.00.

What is the biggest source of revenue for Eli Lilly and Co?

In 2026Q1, the Diabetes-Mounjaro business generated the highest revenue for Eli Lilly and Co, amounting to 6.52B and accounting for 37.02% of total revenue.
KeyAI